SCHEDULE: Vanguard Reduces Stake in Avalo Therapeutics Below 5%

The Vanguard Group has filed an amended Schedule 13G, reporting its beneficial ownership in Avalo Therapeutics Inc. has fallen to 4.43%.

Summary

• The Vanguard Group reported beneficial ownership of 804,084 shares of Avalo Therapeutics Inc. common stock.
• This represents 4.43% of the class of securities, indicating a reduction below the 5% threshold.
• The event requiring this filing occurred on December 31, 2025.
• Vanguard retains shared voting power over 92,039 shares and shared dispositive power over 804,084 shares.
• An internal realignment within The Vanguard Group, Inc. effective January 12, 2026, will result in subsidiaries reporting beneficial ownership separately.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While a reduction in institutional ownership below 5% could be seen as slightly negative, the filing attributes the change to an internal realignment within Vanguard, rather than a specific change in investment thesis for Avalo Therapeutics.

Positives

• NA

Negatives

• The Vanguard Group's beneficial ownership in Avalo Therapeutics Inc. has decreased to 4.43%, falling below the 5% threshold, which could be interpreted as a reduction in institutional conviction.

Risks

• NA

Future Outlook

The Vanguard Group anticipates that certain subsidiaries or business divisions will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. following an internal realignment effective January 12, 2026.

Management Comments

• The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions of subsidiaries, that currently have, or are deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on SEC Release No. 34-39538.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by institutional investors holding more than 5% of a company's stock, or amendments when their stake changes significantly. A reduction below the 5% threshold, as seen here, typically reduces the reporting burden for the investor. For Avalo Therapeutics, a biotechnology company, changes in institutional ownership can sometimes signal shifts in investor sentiment, though in this case, the filing attributes the change to an internal realignment within Vanguard.

Stakeholder Impact

• Shareholders of Avalo Therapeutics Inc. will observe a reduction in The Vanguard Group's reported beneficial ownership, potentially influencing market perception of institutional interest.
• The internal realignment within The Vanguard Group primarily impacts Vanguard's internal reporting structure and its clients, who will continue to have the right to receive dividends and proceeds from the sale of securities.

Next Steps

• The Vanguard Group's subsidiaries or business divisions are expected to report beneficial ownership separately from The Vanguard Group, Inc. after January 12, 2026.

Key Dates

Keywords

Avalo Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake, Biotechnology